Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15,266 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and clinical efficacy of an anti-PD-L1 antibody (c4G12) in dogs with advanced malignant tumours.
Maekawa N, Konnai S, Hosoya K, Kim S, Kinoshita R, Deguchi T, Owaki R, Tachibana Y, Yokokawa M, Takeuchi H, Kagawa Y, Takagi S, Ohta H, Kato Y, Yamamoto S, Yamamoto K, Suzuki Y, Okagawa T, Murata S, Ohashi K. Maekawa N, et al. Among authors: yamamoto k, yamamoto s. PLoS One. 2023 Oct 4;18(10):e0291727. doi: 10.1371/journal.pone.0291727. eCollection 2023. PLoS One. 2023. PMID: 37792729 Free PMC article.
A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma.
Maekawa N, Konnai S, Takagi S, Kagawa Y, Okagawa T, Nishimori A, Ikebuchi R, Izumi Y, Deguchi T, Nakajima C, Kato Y, Yamamoto K, Uemura H, Suzuki Y, Murata S, Ohashi K. Maekawa N, et al. Among authors: yamamoto k. Sci Rep. 2017 Aug 21;7(1):8951. doi: 10.1038/s41598-017-09444-2. Sci Rep. 2017. PMID: 28827658 Free PMC article.
PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma.
Maekawa N, Konnai S, Nishimura M, Kagawa Y, Takagi S, Hosoya K, Ohta H, Kim S, Okagawa T, Izumi Y, Deguchi T, Kato Y, Yamamoto S, Yamamoto K, Toda M, Nakajima C, Suzuki Y, Murata S, Ohashi K. Maekawa N, et al. Among authors: yamamoto k, yamamoto s. NPJ Precis Oncol. 2021 Feb 12;5(1):10. doi: 10.1038/s41698-021-00147-6. NPJ Precis Oncol. 2021. PMID: 33580183 Free PMC article.
Prostaglandin E2-Induced Immune Exhaustion and Enhancement of Antiviral Effects by Anti-PD-L1 Antibody Combined with COX-2 Inhibitor in Bovine Leukemia Virus Infection.
Sajiki Y, Konnai S, Okagawa T, Nishimori A, Maekawa N, Goto S, Watari K, Minato E, Kobayashi A, Kohara J, Yamada S, Kaneko MK, Kato Y, Takahashi H, Terasaki N, Takeda A, Yamamoto K, Toda M, Suzuki Y, Murata S, Ohashi K. Sajiki Y, et al. Among authors: yamamoto k. J Immunol. 2019 Sep 1;203(5):1313-1324. doi: 10.4049/jimmunol.1900342. Epub 2019 Jul 31. J Immunol. 2019. PMID: 31366713 Free PMC article.
Upregulation of PD-L1 Expression by Prostaglandin E2 and the Enhancement of IFN-γ by Anti-PD-L1 Antibody Combined With a COX-2 Inhibitor in Mycoplasma bovis Infection.
Goto S, Konnai S, Hirano Y, Kohara J, Okagawa T, Maekawa N, Sajiki Y, Watari K, Minato E, Kobayashi A, Gondaira S, Higuchi H, Koiwa M, Tajima M, Taguchi E, Uemura R, Yamada S, Kaneko MK, Kato Y, Yamamoto K, Toda M, Suzuki Y, Murata S, Ohashi K. Goto S, et al. Among authors: yamamoto k. Front Vet Sci. 2020 Feb 20;7:12. doi: 10.3389/fvets.2020.00012. eCollection 2020. Front Vet Sci. 2020. PMID: 32154274 Free PMC article.
Novel, infection-free, advanced hemostatic material: physical properties and preclinical efficacy.
Katsuyama S, Miyazaki Y, Kobayashi S, Nakagawa Y, Yamamoto K, Tanaka K, Makino T, Takahashi T, Kurokawa Y, Yamasaki M, Mori M, Doki Y, Nakajima K. Katsuyama S, et al. Among authors: yamamoto k. Minim Invasive Ther Allied Technol. 2020 Oct;29(5):283-292. doi: 10.1080/13645706.2019.1627373. Epub 2019 Jun 12. Minim Invasive Ther Allied Technol. 2020. PMID: 31187670
Endoscopic application of novel, infection-free, advanced hemostatic material: Its usefulness to upper gastrointestinal oozing.
Kubo Y, Kobayashi S, Yamamoto K, Nakagawa Y, Yamashita K, Saito T, Tanaka K, Makino T, Yamamoto K, Takahashi T, Kurokawa Y, Yamasaki M, Eguchi H, Doki Y, Nakajima K. Kubo Y, et al. Among authors: yamamoto k. DEN Open. 2021 Aug 22;2(1):e25. doi: 10.1002/deo2.25. eCollection 2022 Apr. DEN Open. 2021. PMID: 35310741 Free PMC article.
All-trans retinoic acid suppresses bone morphogenetic protein 4 in mouse diabetic nephropathy through a unique retinoic acid response element.
Tamaki M, Tominaga T, Fujita Y, Koezuka Y, Ichien G, Murakami T, Kishi S, Yamamoto K, Abe H, Nagai K, Doi T. Tamaki M, et al. Among authors: yamamoto k. Am J Physiol Endocrinol Metab. 2019 Mar 1;316(3):E418-E431. doi: 10.1152/ajpendo.00218.2018. Epub 2019 Jan 2. Am J Physiol Endocrinol Metab. 2019. PMID: 30601699 Free article.
Urinary IgG4 and Smad1 Are Specific Biomarkers for Renal Structural and Functional Changes in Early Stages of Diabetic Nephropathy.
Doi T, Moriya T, Fujita Y, Minagawa N, Usami M, Sasaki T, Abe H, Kishi S, Murakami T, Ouchi M, Ichien G, Yamamoto K, Ikeda H, Koezuka Y, Takamatsu N, Shima K, Mauer M, Nagai K, Tominaga T. Doi T, et al. Among authors: yamamoto k. Diabetes. 2018 May;67(5):986-993. doi: 10.2337/db17-1043. Epub 2018 Feb 28. Diabetes. 2018. PMID: 29490904
Development of a score model to predict long-term prognosis after community-onset pneumonia in older patients.
Takazono T, Namie H, Nagayoshi Y, Imamura Y, Ito Y, Sumiyoshi M, Ashizawa N, Yoshida M, Takeda K, Iwanaga N, Ide S, Harada Y, Hosogaya N, Takemoto S, Fukuda Y, Yamamoto K, Miyazaki T, Sakamoto N, Obase Y, Sawai T, Higashiyama Y, Hashiguchi K, Funakoshi S, Suyama N, Tanaka H, Yanagihara K, Izumikawa K, Mukae H. Takazono T, et al. Among authors: yamamoto k. Respirology. 2024 May 20. doi: 10.1111/resp.14752. Online ahead of print. Respirology. 2024. PMID: 38769707
15,266 results
You have reached the last available page of results. Please see the User Guide for more information.